Ology Bioservices, a biologics contract development and manufacturing organization (CDMO), said that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine. The contract value is $6.3 million.   The vaccine candidate ATI-1701 (F. tularensis ΔclpB) is a novel attenuated version derived from the virulent SCHU S4 strain of tularemi...